Drug Profile
Research programme: neuropathic pain therapeutics - QUE Oncology
Alternative Names: Q 201Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator QUE Oncology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 07 Jun 2016 Preclinical trials in Neuropathic pain in USA (unspecified route) before June 2016